GLP-1 and Fatty Liver: What the ESSENCE Trial Showed About MASH

Fatty liver disease is the most common chronic liver condition in the world, and for most of its history there was nothing to prescribe for it. Clinicians could tell you to lose weight, and the data behind that advice was genuinely strong, but very few people managed to lose enough weight for long enough to reverse the damage. That gap is why the ESSENCE trial, published in the New England Journal of Medicine in April 2025, mattered so much. It was the first large phase 3 trial to show that a GLP-1 medication could both clear inflammation from the liver and reverse scarring in people with biopsy confirmed disease.

The result led to an FDA approval in August 2025, which made semaglutide 2.4 mg the second medication ever cleared for metabolic dysfunction associated steatohepatitis, usually shortened to MASH. It also put a familiar weight loss injection at the center of a liver disease conversation that affects roughly one in three adults.

This article explains what MASH is and how it differs from ordinary fatty liver, what ESSENCE actually measured, why weight loss matters so much for the liver, how semaglutide compares with the other treatments now in play, and where the research is still incomplete. It is educational content about published research and not medical advice. Anyone with known or suspected liver disease should be evaluated by a clinician before starting any GLP-1 medication.

MASH is the inflammatory, progressive stage of fatty liver disease, and the difference between it and simple fatty liver is whether the fat is actively injuring liver cells. Simple fatty liver, called steatosis, means that more than 5 percent of liver cells contain fat droplets. On its own, steatosis is usually harmless and often reversible. MASH is diagnosed when that fat is accompanied by inflammation and a specific kind of cell injury called ballooning, which triggers the scarring process known as fibrosis.

The terminology changed in June 2023 when an international consensus panel replaced the older names nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) with metabolic dysfunction associated steatotic liver disease (MASLD) and metabolic dysfunction associated steatohepatitis (MASH). The new definition requires at least one cardiometabolic risk factor, such as excess weight, elevated blood sugar, high blood pressure or abnormal blood lipids, which reflects the reality that this is a metabolic disease that happens to show up in the liver.

Fibrosis is graded on a five point scale from F0 (no scarring) to F4 (cirrhosis). Stage F2 is called significant fibrosis and stage F3 is called advanced fibrosis. These two stages are the target zone for treatment because the liver can still recover, but the risk of progressing to cirrhosis, liver failure or liver cancer rises sharply from here. Fibrosis stage, more than any other feature of the disease, predicts who will eventually die of liver related causes.

MASLD affects roughly 30 percent of adults globally, with some 2023 estimates placing the figure closer to 38 percent, and the prevalence rises to about 70 percent in people with type 2 diabetes or obesity. Around 5 percent of the general adult population has progressed to MASH, and a meaningful fraction of those people have significant fibrosis without knowing it, because the condition causes no symptoms until the liver is badly damaged.

The disease is also increasingly common in women after menopause. Estrogen appears to protect the liver from fat accumulation, and the loss of that protection, combined with the shift toward abdominal fat storage that accompanies perimenopause, means that women in their fifties and sixties develop MASLD at rates that catch up to and can exceed those of men the same age.

Most people with MASLD will not die of liver disease. The leading cause of death in this population is cardiovascular disease, which makes sense given that the same insulin resistance driving fat into the liver also drives atherosclerosis. That overlap is one reason GLP-1 medications, which have separately been shown to reduce heart attacks and strokes, are such a natural fit for this condition.

ESSENCE showed that semaglutide 2.4 mg weekly nearly doubled the rate of MASH resolution and increased the rate of fibrosis improvement by about two thirds compared with placebo over 72 weeks. The trial, led by Arun Sanyal and published on April 30, 2025, enrolled 1,197 adults with biopsy confirmed MASH and F2 or F3 fibrosis across 37 countries. Participants were randomized two to one to semaglutide or placebo, with semaglutide titrated over 16 weeks to the 2.4 mg maintenance dose used in the STEP weight loss trials.

The trial was built in two parts. Part 1, the analysis published in 2025, examined the first 800 participants at 72 weeks using repeat liver biopsy. Part 2 continues to follow all 1,197 participants for 240 weeks to see whether the biopsy improvements translate into fewer cases of cirrhosis, liver failure, transplant and death. The FDA approval was granted on an accelerated basis pending those longer results.

The two coprimary endpoints both cleared their statistical thresholds. Resolution of steatohepatitis without worsening of fibrosis occurred in 62.9 percent of the semaglutide group versus 34.3 percent of the placebo group, a difference of 28.7 percentage points. Improvement in fibrosis by at least one stage without worsening of steatohepatitis occurred in 36.8 percent versus 22.4 percent, a difference of 14.4 percentage points. A combined endpoint requiring both MASH resolution and fibrosis improvement was met by 32.7 percent on semaglutide versus 16.1 percent on placebo.

Weight loss averaged 10.5 percent on semaglutide versus 2.0 percent on placebo, and liver enzymes, liver stiffness on elastography and inflammatory markers all improved in parallel. Gastrointestinal side effects followed the familiar GLP-1 pattern: nausea affected roughly 36 percent of the semaglutide group versus 13 percent on placebo, with diarrhea, constipation and vomiting also more common. Serious adverse events were similar between arms.

The placebo response deserves a comment. A third of placebo participants had their MASH resolve, which is high for a liver trial and reflects how much lifestyle counseling and general attention people receive inside a clinical trial. The semaglutide effect is measured against that backdrop, which makes the 28.7 point gap more impressive rather than less.

Weight loss matters because the liver responds to it in a graded way, with each additional increment of loss unlocking a deeper level of repair. The clearest evidence comes from a 2015 study by Eduardo Vilar-Gomez and colleagues, who followed 293 people with biopsy confirmed NASH through a year of intensive lifestyle intervention and then repeated the biopsy. The results lined up on a staircase.

People who lost 5 percent or more of their body weight reduced their liver fat, and people who lost 7 percent or more saw resolution of steatohepatitis in most cases. Among those who lost 10 percent or more, 90 percent had their NASH resolve and 45 percent had their fibrosis regress by at least one stage. The catch was that only 10 percent of participants reached the 10 percent threshold, and fewer than 30 percent reached even 5 percent, despite a year of structured support.

That gap between what works and what people can sustain is the entire rationale for a drug. The average semaglutide participant in ESSENCE lost 10.5 percent, which put the typical person right at the level where fibrosis begins to reverse. Semaglutide did not invent a new mechanism for liver repair so much as it made the existing one reachable.

Semaglutide produced the largest MASH resolution rate of any phase 3 trial published so far, but resmetirom remains the only other approved option and several drugs in development have posted phase 2 numbers that are as good or better. The comparisons below come from separate trials with different populations and designs, so they are a guide to the landscape rather than a head to head ranking.

Resmetirom (Rezdiffra) was approved in March 2024 as the first MASH medication. It is a thyroid hormone receptor beta agonist, which means it acts directly on liver cells to increase fat burning without the systemic effects of thyroid hormone. In the 966 person MAESTRO-NASH trial, MASH resolution occurred in 25.9 percent at 80 mg and 29.9 percent at 100 mg versus 9.7 percent on placebo, and fibrosis improvement occurred in 24.2 percent and 25.9 percent versus 14.2 percent. Resmetirom causes minimal weight loss, which makes it a candidate for people who cannot tolerate GLP-1 medications or who do not need to lose weight.

Tirzepatide, the dual GIP and GLP-1 agonist sold as Mounjaro and Zepbound, was tested in the 190 person phase 2 SYNERGY-NASH trial published in 2024. At 52 weeks, MASH resolution occurred in 44 percent at 5 mg, 56 percent at 10 mg and 62 percent at 15 mg versus 10 percent on placebo, and fibrosis improvement occurred in 51 to 55 percent versus 30 percent. Those numbers are striking, but the trial was small and a phase 3 program has not yet reported.

Survodutide, a dual glucagon and GLP-1 agonist in development, showed improvement in MASH without worsening fibrosis in 47 to 62 percent of participants versus 14 percent on placebo in a 293 person phase 2 trial published in 2024. The glucagon component is thought to add direct hepatic fat burning on top of the appetite effect, and phase 3 trials are underway.

An earlier phase 2 trial of daily semaglutide, published by Philip Newsome in 2021, found MASH resolution in 59 percent of people on 0.4 mg daily versus 17 percent on placebo but did not show a significant fibrosis benefit (43 percent versus 33 percent). ESSENCE, with more than three times the participants, resolved that uncertainty in semaglutide's favor.

Semaglutide improves the liver almost entirely through indirect routes, because hepatocytes express few if any functional GLP-1 receptors. The primary route is weight loss, which lowers the flow of free fatty acids from adipose tissue into the liver and reduces the amount of new fat the liver manufactures from sugar, a process called de novo lipogenesis. Improved insulin sensitivity in muscle and fat tissue compounds the effect by lowering the insulin and glucose levels that drive fat storage in the first place.

A second route is inflammation. GLP-1 medications lower C reactive protein and other inflammatory markers by roughly a third, and reduced systemic inflammation appears to calm the immune cells inside the liver that drive ballooning injury and fibrosis. A third contribution comes from the gut itself: slower gastric emptying and changed bile acid signaling alter the metabolic messages that reach the liver through the portal vein.

The practical consequence is that the liver benefit tracks weight loss closely. ESSENCE participants who lost more weight were more likely to have their fibrosis improve, and the modest benefit of the earlier daily semaglutide trial was consistent with its smaller average weight loss.

Fatty liver is usually diagnosed and monitored with a sequence of blood tests and imaging that identifies who needs a biopsy and who does not. The first step is typically the FIB-4 score, a formula that combines age, two liver enzymes (AST and ALT) and platelet count. A FIB-4 below 1.3 indicates low risk of advanced fibrosis, a score above 2.67 indicates high risk, and scores in between are indeterminate and call for a second test.

The most common second test is transient elastography, marketed as FibroScan, which measures liver stiffness in kilopascals by sending a vibration through the liver and timing how fast it travels. Stiffness below 8 kPa makes advanced fibrosis unlikely, while values above 12 kPa suggest advanced fibrosis and warrant specialist referral. The same device measures liver fat through a reading called the controlled attenuation parameter, or CAP.

MRI based fat measurement (MRI proton density fat fraction) is the most precise noninvasive way to track liver fat over time, and a relative reduction of 30 percent or more in liver fat on MRI has been shown to predict histologic improvement on biopsy. Liver biopsy remains the reference standard for trials and for confirming diagnosis, but in routine practice it is reserved for cases where noninvasive tests disagree or the diagnosis is uncertain.

If you are on a GLP-1 medication and want to know whether your liver is benefiting, a repeat FIB-4 from routine blood work and a follow up FibroScan after six to twelve months are the tests most clinicians use.

The research does not yet show whether biopsy improvements translate into fewer cases of cirrhosis, liver failure or liver cancer, and it does not show a benefit in people who already have cirrhosis. The first question is what Part 2 of ESSENCE is designed to answer over 240 weeks, and the FDA approval remains conditional on that result.

The cirrhosis question has a partial and discouraging answer. A 2023 trial by Rohit Loomba tested semaglutide 2.4 mg in 71 people with MASH related compensated cirrhosis and found no significant improvement in fibrosis after 48 weeks, even though weight loss and liver enzymes improved. Once the scarring has reached F4, the liver may need more than metabolic improvement to remodel, and the current approval excludes cirrhosis for that reason.

Durability is a third open question. Weight regain after stopping semaglutide is well documented, and the liver is expected to follow the weight. There is no evidence that a course of treatment resets the liver permanently, so the working assumption is that the benefit persists only as long as weight loss does.

Finally, ESSENCE excluded people who drank heavily, and the newer category of MetALD, meaning metabolic liver disease with moderate alcohol intake, has not been studied specifically. Whether GLP-1 medications help people whose liver disease has both metabolic and alcohol components is an active research question, and early data on reduced alcohol cravings with GLP-1 medications makes it a promising one.

The ESSENCE trial gave people with MASH and significant fibrosis something that did not exist two years ago: a medication that clears liver inflammation in a majority of patients and reverses scarring in more than a third, with the same cardiovascular and metabolic benefits that made semaglutide famous in the first place. The effect works mainly through weight loss, which means it depends on staying on the medication and pairing it with the diet and exercise changes that trial participants also received.

If you carry excess weight and have elevated liver enzymes, a fatty liver on ultrasound or type 2 diabetes, asking your clinician for a FIB-4 score is a reasonable first step. It costs nothing beyond routine blood work, and it tells you whether the liver deserves a closer look before any conversation about treatment begins.